You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Express Scripts
Boehringer Ingelheim
Harvard Business School
Dow

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Litigation Details for Roche Palo Alto LLC v. Apotex, Inc. (N.D. Cal. 2005)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Roche Palo Alto LLC v. Apotex, Inc.
The small molecule drugs covered by the patent cited in this case are   Start Trial and   Start Trial .

Details for Roche Palo Alto LLC v. Apotex, Inc. (N.D. Cal. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-08-19 22 infringement of United 3 States Patent No. 5,110,493 (“the ’493 patent”) by Defendants and Counter-Plaintiffs…seeking, inter alia, declaratory relief that the ‘493 patent be adjudged 7 invalid and unenforceable. 8 …2005 18 August 2006 3:05-cv-02116-MJJ Patent District Court, N.D. California External link to document
2005-12-29 32 Defendants’ claim that the U.S. Patent No. 5,110,493 (“the ‘493 patent”) is obvious, and specifically …references that Defendants allege render the ‘493 patent obvious. As the facts now stand, §the ‘492 is entitled…Document32 Filed12/29/05 Page 2§01°3 that the ‘492 patent was invalid based on obviousness and had failed… by clear and convincing evidence that the ‘492 patent is invalid. See ()akley, Inc. v. Sunglass Hut lm…public interest strongly favors the enforcement of patent§ rights and encouraging innovation, and Defendants External link to document
2007-06-01 36 inducement of 8 infringement of U.S. Patent No, 5, 110, 493 (“the ‘493 patent”). Defendants are generic 9 … of ANDA 76-109 infringed the ‘493 patent and that the ‘493 patent was valid 17 and enforceable. The…Defendants’ filing of ANDA 76-308 infringes the ‘493 patent. 12 The parties have previously litigated…involving Defendants’ infringement of the 13 ‘493 patent. That previous case concerned Defendants’ filing… a decision that ANDA 76-308 infringes the ‘493 patent or (b) a preliminary 26 injunction prohibiting External link to document
2007-09-11 66 that solution would infringe U.S. Patent No. 5,110,493 (“the ‘493 Patent”) …-308 infringes claims 1-5, 15-16 of U.S. Patent No. 5,110,493, and GRANTS …drug that is claimed in a patent or the use of which is claimed in a patent. 28 U.S.C. § 271(e). United… Yet Defendants point to nothing in the patent claims, patent specification, prosecution history, or …the Court’s findings did not draw on the patent claims, patent External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.